Artrya has signed its first inbound US customer outside its foundation and research relationships, securing a five-year HonorHealth agreement with a minimum value of US$0.5 million. The Salix platform will be deployed across the Arizona health system’s nine-hospital CCTA network.
- Five-year HonorHealth agreement with minimum contracted value of US$0.5 million
- Artrya’s fifth US commercial customer and first inbound customer
- Salix deployment across nine HonorHealth acute-care hospitals
- Additional usage-based revenue possible from Plaque and Flow modules
- Longer-term Centre of Excellence proposal remains exploratory
HonorHealth becomes Artrya’s fifth US customer
Artrya Limited (ASX:AYA) has added a major Arizona health system to its US commercial roster, signing a five-year agreement with HonorHealth carrying a minimum contracted value of US$0.5 million. The deal makes HonorHealth Artrya’s fifth US commercial customer and, more significantly, its first inbound customer secured outside its foundation customers and SAPPHIRE research programs.
That distinction gives the contract a different flavour from Artrya’s earlier US wins. The company said HonorHealth approached the relationship through its evaluation of Salix, rather than through an existing foundation or research arrangement. Artrya’s previous Huntsville five-year agreement had converted its first SAPPHIRE Study participant into a commercial customer, making the HonorHealth agreement an early test of whether broader market awareness can generate customers beyond those established channels.
Nine-hospital deployment expands the Salix footprint
HonorHealth operates nine acute-care hospitals across Phoenix and Scottsdale that provide coronary CT angiography, supported by HonorHealth Heart Care’s network of 40 cardiac specialist offices. The system serves approximately five million people and includes more than 17,000 team members and 4,000 medical staff.
Salix Coronary Anatomy will generate recurring software subscription revenue under the agreement. Additional fee-per-scan revenue could come from Salix Coronary Plaque and, subject to FDA clearance, Salix Coronary Flow. The company has not provided expected scan volumes, revenue timing or an estimate of the potential usage-based contribution, so the US$0.5 million minimum should not be read as a forecast of the contract’s total value.
Implementation is the next commercial test
Artrya described HonorHealth as its second-largest customer and said the system-wide integration will extend across the hospitals in the network that provide CCTA. The company’s immediate focus is implementation and clinical adoption, while HonorHealth has said it selected Salix to help manage growing workflows and support earlier and more precise decisions in coronary artery disease care.
The companies also intend to explore a cardiovascular imaging Centre of Excellence in Arizona, potentially involving real-world clinical evidence, education and training. That longer-term concept is not a committed deliverable under the disclosed agreement. HonorHealth’s academic affiliation with Arizona State University’s John Shufeldt School of Medicine and Medical Engineering may also create opportunities for collaborative AI research, but those opportunities remain prospective rather than contracted revenue.
Bottom Line?
The contract adds a valuable reference customer and a five-year revenue floor, but its commercial significance will depend on implementation, scan volumes and whether the additional Salix modules secure regulatory clearance and clinical uptake.
Questions in the middle?
- How quickly will Salix be implemented across HonorHealth’s nine-hospital CCTA network?
- What scan volumes and usage-based revenue will the deployment ultimately generate?
- When, and on what evidence, could Salix Coronary Flow receive FDA clearance?